The Destiny Breast 11 trial compared a new drug to a chemotherapy regimen (ACTHP) that many US oncologists no longer use. This choice of a less common control arm makes it difficult for them to directly compare the new treatment's efficacy against their own current standard (TCHP), complicating adoption.

While smaller trials like KEYNOTE-905 can show dramatic results, they are subject to more statistical noise. Larger, thousand-patient studies like B15 and Niagara, with narrower confidence intervals, are considered closer to the true effect size and provide a more stable foundation for establishing the standard of care.

Experts caution that the new consensus definition of cCR, combining imaging and cystoscopy, is for clinical trials only. Applying it prematurely in routine practice could harm patients, as its correlation with true pathologic response is still being validated with modern therapies.

The trial's 57.1% pathologic complete response (pCR) rate is deceptively conservative. It categorized patients who responded well but declined surgery as non-responders, suggesting the treatment's true biological efficacy is even higher than the already impressive reported figure.

The excitement around new systemic therapies has already created a "Wild West" environment where patient and surgeon motivation for cystectomy has plummeted. This cultural shift is outpacing prospective data, raising concerns that patients are making major decisions outside of rigorous clinical trials.

Advanced diagnostics like Signatera ctDNA and therapies such as adjuvant nivolumab, while becoming standard in the US, are often unavailable in Europe and elsewhere. This creates a significant gap in care, making many cutting-edge discussions purely theoretical for a large portion of the world's oncologists and patients.

Designing a randomized trial to compare surgery versus systemic therapy alone is nearly impossible. A previous attempt, the SPARE study, failed to recruit because clinicians and patients already had strong pre-existing opinions on the best course of action, a bias that persists today.

The efficacy of new bladder cancer drugs in single-arm trials is hard to assess because of concurrent improvements in surgical technology. Modern scopes allow for more complete resection of CIS tumors, meaning a "complete response" may be due to the surgery before the drug is even administered, not the drug itself.

While the TAR-200 gemcitabine-releasing device showed lower efficacy than systemic EV-pembrolizumab, its value proposition is logistical simplicity. As a treatment administered entirely by urologists in-office via cystoscopy, it offers a less complex and potentially less toxic alternative, making it an attractive option based on practice workflow rather than superior outcomes alone.